Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.56 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.55 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307975 | 0.85 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2AKR1C2AKR1C3 | |
| SCHEMBL1307808 | 0.84 | KDM4E (0.64) | MEN1KMT2AKCNK2KCNK10AKR1C2 | |
| SCHEMBL6440417 | 0.84 | GRIK1 (0.62) | MEN1KMT2AKCNK2KCNK10SMN1; SMN2 | |
| SCHEMBL1307972 | 0.82 | TP53 (0.70) | MEN1KMT2AKCNK2KCNK10AKR1C2 | |
| SCHEMBL1308673 | 0.82 | AKR1C2 (0.62) | MEN1KMT2AKCNK2KCNK10SMN1; SMN2 | |
| SCHEMBL1310012 | 0.81 | AKR1C2 (0.60) | MEN1KMT2AKCNK2KCNK10AKR1C2 | |
| SCHEMBL1307640 | 0.80 | ALDH1A1 (0.60) | MEN1KMT2AAKR1C2AKR1C1AKR1C4 | |
| SCHEMBL1307557 | 0.80 | TP53 (0.67) | MEN1KMT2ASMN1; SMN2AKR1C2AKR1C1 | |
| SCHEMBL6817565 | 0.79 | KMT2A (0.60) | MEN1KMT2AKCNK2KCNK10SMN1; SMN2 | |
| SCHEMBL9513479 | 0.79 | MAPT (0.80) | MEN1KMT2AKCNK2KCNK10AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | MEN1 2312/4885KMT2A 1570/4885KCNK2 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.